Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III ...

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) ...

Roche entered into a Licensing, Development, and Commercialisation agreement with Prothena in December 2013 to develop and ...

Data from the POLARGO trial potentially establishes a new standard of care for patients with R/R DLBCL ineligible for ...

During a live event, Ahmad Tarhini, MD, PhD, and participants discussed how to use combination immunotherapy in patients with ...

In a multicenter Phase III trial spanning eight leading clinical hospitals in China, Azstarys demonstrated statistically significant improvements over placebo in primary and secondary efficacy ...

BASEL, Switzerland I June 15, 2025 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ ...